Terminated PHASE2 INTERVENTIONAL 2-arm NCT00280007

Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma

AVATACE-1: Bevacizumab (Avastin®) as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC) a Pilot Trial

Sponsor: Medical University of Vienna

Conditions Hepatocellular Carcinoma

Interventions bevacizumab

Updated 5 times since 2017 Last updated: Apr 21, 2010 Started: Jan 31, 2006 Primary completion: Dec 31, 2009 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Safety concerns in the treatment arm

Other terminated trials from Medical University of Vienna

See all terminations from Medical University of Vienna

Other Hepatocellular Carcinoma trials with similar outcome

Browse all Hepatocellular Carcinoma trials

Listed as NCT00280007, this PHASE2 trial focuses on Hepatocellular Carcinoma and remains terminated or withdrawn. Sponsored by Medical University of Vienna, it has been updated 5 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Vienna

Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria